Sun Pharmaceutical Industries Ltd up by 10.06% | Espresso Market Updates


Espresso shot of the day – Sun Pharmaceutical Industries Ltd up by 10.06 percent

July 30, 2021
Espresso shot of the day – Sun Pharmaceutical Industries Ltd up by 10.06 percent

SUN PHARMACEUTICAL INDUSTRIES LTD 774.00 (+10.06%) BSE – INE044A01036 | 30TH JULY 2021

Sun Pharmaceutical Industries Ltd. (Sun Pharma) is the fourth largest specialty generic pharmaceutical company in the world, with global revenues of over USD 4.5 billion. Supported by more than 40 manufacturing facilities, we provide high-quality, affordable medicines, trusted by healthcare professionals and patients, to more than 100 countries across the globe.

Recent Drivers

  • On July 30, 2021, Sun Pharma reported a consolidated net profit of Rs 1,444 crores for the quarter ended June as against a consolidated net loss of Rs 1,655 crores in the year-ago quarter.
  • On July 30, 2021, the company’s consolidated revenues in the quarter rose 28% year-on-year to Rs 9,719 crores.
  • On July 26, 2021, Sun Pharma said it has signed license and supply agreements with Cassiopea SpA for acne treatment drug Winlevi in the US and Canada. Sun Pharma will have the exclusive right to commercialise Winlevi in the United States and Canada, and Cassiopea will be the exclusive supplier of the product.
  • On July 1, 2021, Sun Pharma announced the launch of a special initiative Sunkalp for the welfare of doctors, their families and the community. Further mentioned initiatives will be rolled out in a phased manner: Mental health support for doctors and their families, webinars for doctors on mental health by experts, donation of COVID-19 medicines (Phase 2), post-Doctorate educational sponsorship (Phase 2), educational aid for children of doctors who lost their lives to COVID-19 (Phase 2). Sun Pharma has committed Rs 100 crores towards these initiatives, which includes donation of COVID-19 medicines to communities at large through local and state government institutions.
  • On June 2, 2021, Sun Pharma said it has entered into a licensing agreement with Ferring Pharmaceuticals to commercialise innovative obstetric drug Caritec in India.
  • On May 10, 2021, Sun Pharma announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company for expanding access to Lilly’s drug, Baricitinib in India. Sun Pharma will manufacture and distribute the drug in India.
(Sources: The Economic Times, BSEIndia, Business Standard,

Technical Force*

  • S&P BSESensex month till date gain up by 0.20%
  • Traded on new 52-week-high value of 780.10
  • Spurt in volume by more than 11.65 times compare to previous vol. | 3 months avg volume: 3,03,771
  • Quantity traded: 20,34,169 | Deliverable quantity: 6,51,396 (32.02%)
  • Stock price has jumped more than 65% from one-year-low level: 452.60 (Oct 29, 2020)
  • Daily RSI (14) is in Overbought territory today
  • 52-week-high: 780.10 | 52-week-low: 452.60

Key Pivot  (Yearly)










Pivot Point










Fibonacci Pivot










Today’s Close




10 DAY


20 DAY


50 DAY


200 DAY


Some Key Ratios (Source: BSE)

Market Cap: 1,85,703.94 crores

PE: 86.79

OPM%: 19.80

ROE%: 8.55

Promoters holding%: 54.48

Prev. Close: 703.25

*Chart And Technical Force data taken from the Binge desktop app.

The scope and usability of this information/data is time-sensitive and market-based, and as such the same may become outdated for the investment decisions of clients, for which Sharekhan comtrade bears no responsibility. References to securities do not constitute a recommendation to buy, sell or hold such securities. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document and should consult his own advisors to determine the merits and risks of such an investment. Sharekhan Comtrade Private Limited is under no obligation to update the information in this document from time-to-time.

Chandresh Khona
by Chandresh Khona

Product Offerings Head

A teacher, writer, travel buff and now Espresso's Product Offerings Head. Ten years here has allowed me to lead the digital team at Sharekhan. My true passion lies in stock market charts.